EGFR and neoplasm: We present in this article a mechanistic model built based on those guidelines with the additional validation step (fifth step), integrating multiscale phenomena, with a context of use to predict tumor evolution and disease progression over time of EGFR-mutant LUAD patients treated with gefitinib.